US bill approval protects biomaterials suppliers
This article was originally published in Clinica
Executive Summary
The US Senate Commerce Committee approved a tort reform bill on May 1st that among other things would protect biomaterial suppliers from lawsuits alleging harm from an implantable medical device. The bill, sent to the Senate floor on a party-line 11-9 vote, is similar to the measure passed by Congress last year that would limit damage awards in lawsuits over faulty products. That bill was vetoed by President Clinton although he said at the time he supported the biomaterials provision.